H.C. Wainwright lowered the firm’s price target on Roivant Sciences to $17 from $18 and keeps a Buy rating on the shares. Given the current sales growth, the analyst reduced Vtama expectations in psoriasis. The firm says that while brepocitinib “disappointingly missed” in systemic lupus erythematosus, it remains constructive on brepocitinib in non-infectious uveitis and dermatomyositis. H.C. Wainwright awaits Roivant’s capital allocation strategy following the sale of Telavant to Roche.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ROIV:
- Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
- Roivant Sciences reports Q3 EPS $6.03, consensus (32c)
- ROIV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jefferies ‘encouraged thus far’ by Arbutus patent hearing
- JPMorgan biotech analysts to hold an analyst/industry conference call
